The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...

It’s important to spot early signs of sleep disorders to stay healthy. If you ignore these signs, they can turn into bigger ...

Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking ...

Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...

Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children ...

Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has ...

Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of ...

Today’s AI-fueled era of the “Magnificient Seven” technology stocks is dominating the US stock market. However, investing ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

At its official opening, Los Alamos Medical Center Chief Executive Officer Tracie Stratton noted there are not enough options ...

For Wendy, playfully jumping on the bed as a child led to panic when, suddenly, her limbs ceased to function, and she dropped ...

The affirmation follows recent developments from Takeda Pharmaceutical Company (NYSE:TAK) regarding its narcolepsy medication, which may have implications for Alkermes' treatment in the same drug ...